Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

A New Inflammatory Prognostic Index, Based on C-reactive Protein, the Neutrophil to Lymphocyte Ratio and Serum Albumin is Useful for Predicting Prognosis in Non-Small Cell Lung Cancer Cases

  • Dirican, Nigar (Department of Chest Diseases, Faculty of Medicine, Suleyman Demirel University) ;
  • Dirican, Ahmet (Department of Medical Oncology, Faculty of Medicine, Celal Bayar University) ;
  • Anar, Ceyda (Department of Chest Diseases, Dr. Suat Seren Chest Diseases and Surgery Training and Research Hospital) ;
  • Atalay, Sule (Department of Chest Diseases, Faculty of Medicine, Suleyman Demirel University) ;
  • Ozturk, Onder (Department of Chest Diseases, Faculty of Medicine, Suleyman Demirel University) ;
  • Bircan, Ahmet (Department of Chest Diseases, Faculty of Medicine, Suleyman Demirel University) ;
  • Akkaya, Ahmet (Department of Chest Diseases, Faculty of Medicine, Suleyman Demirel University) ;
  • Cakir, Munire (Department of Chest Diseases, Faculty of Medicine, Suleyman Demirel University)
  • Published : 2016.12.01
⟨ Previous Next ⟩

Abstract

Purpose: We aimed to establish an inflammatory prognostic index (IPI) in early and advanced non-small cell lung cancer (NSCLC) patients based on hematologic and biochemical parameters and to analyze its predictive value for NSCLC survival. Materials and Methods: A retrospective review of 685 patients with early and advanced NSCLC diagnosed between 2009 and 2014 was conducted with collection of clinical, and laboratory data. The IPI was calculated as C-reactive protein ${\times}$ NLR (neutrophil/ lymphocyte ratio)/serum albumin. Univariate and multivariate analyses were performed to assess the prognostic value of relevant factors. Results: The optimal cut-off value of IPI for overall survival (OS) stratification was determined to be 15. Totals of 334 (48.8%) and 351 (51.2%) patients were assigned to high and low IPI groups, respectively. Compared with low IPI, high IPI was associated with older age, greater tumor size, high lymph node involvement, distant metastases, advanced stage and poor performance status. Median OS was worse in the high IPI group (low vs high, 8.0 vs 34.0 months; HR, 3.5; p<0.001). Progression free survival values of the patients who had high vs low IPI were determined 6 months (95% CI:5.3-6.6) and 14 months (95% CI:12.1-15.8), respectively (HR; 2.4, P<0.001). On multivariate analysis, stage, performance status, lactate dehydrogenase and IPI were independent prognostic factors for OS. Subgroup analysis showed IPI was generally a significant prognostic factor in all clinical variables. Conclusion: The described IPI may be an inexpensive, easily accessible and independent prognostic index for NSCLC patients, useful for clinical practice.

Keywords

References

  1. Albain KS, Crowley JJ, LeBlanc M, Livingston RB (1991). Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol, 9, 1618-26. https://doi.org/10.1200/JCO.1991.9.9.1618
  2. Azab B, Chainani V, Shah N, McGinn JT (2013). Neutrophil-lymphocyte ratio as a predictor of major adverse cardiac events among diabetic population: A 4-year follow-up study. Angiology, 64, 456-5. https://doi.org/10.1177/0003319712455216
  3. Balkwill F, Mantovani A (2001). Inflammation and cancer: back to Virchow?. Lancet, 357, 539-45. https://doi.org/10.1016/S0140-6736(00)04046-0
  4. Celikbilek M, Dogan S, Ozbakir O, et al (2013). Neutrophil- lymphocyte ratio as a predictor of disease severity in ulcerative colitis. J Clin Lab Anal, 27, 72-6. https://doi.org/10.1002/jcla.21564
  5. Coussens LM, Werb Z (2002). Inflammation and cancer. Nature, 420, 860-7. https://doi.org/10.1038/nature01322
  6. Detterbeck FC, Postmus PE, Tanoue LT (2013). The stage classification of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest, 143, 191-210. https://doi.org/10.1378/chest.12-2354
  7. Devesa SS, Bray F, Vizcaino AP, Parkin DM (2015). International lung cancer trends by histologic type: male: female differences diminishing and adenocarcinoma rates rising. Int J Cancer, 117, 294-99.
  8. Dirican A, Varol U, Kucukzeybek Y, et al (2014). Treatment of metastatic colorectal cancer with or without bevacizumab: can the neutrophil/lymphocyte ratio predict the efficiency of bevacizumab?. Asian Pac J Cancer Prev, 15, 4781-6. https://doi.org/10.7314/APJCP.2014.15.12.4781
  9. Engan T, Hannisdal E (1990). Blood analyses as prognostic factors in primary lung cancer. Acta Oncol, 29, 151-4. https://doi.org/10.3109/02841869009126536
  10. Espinosa E, Feliu J, Zamora P, et al (1995). Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer. Lung Cancer, 12, 67-76. https://doi.org/10.1016/0169-5002(95)00407-R
  11. Forrest LM, McMillan DC, McArdle CS (2003). Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable nonsmallcell lung cancer. Br J Cancer, 89, 1028-30. https://doi.org/10.1038/sj.bjc.6601242
  12. Gagnon B, Agulnik JS, Gioulbasanis I, et al (2013). Montreal prognostic score: estimating survival of patients with nonsmall cell lung cancer using clinical biomarkers. Br J Cancer, 109, 2066-71. https://doi.org/10.1038/bjc.2013.515
  13. Gu XB, Tian T, Tian XJ, Zhang XJ (2015). Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis. Sci Rep, 24, 12493.
  14. Gulen ST, Karadag F, Karul AB, et al (2012). Adipokines and systemic inflammation in weight-losing lung cancer patients. Lung, 190, 327-32. https://doi.org/10.1007/s00408-011-9364-6
  15. Harrison M (2015). Erythrocyte sedimentation rate and C-reactive protein. Aust Prescr, 38, 93-4. https://doi.org/10.18773/austprescr.2015.034
  16. He X, Zhou T, Yang Y, et al (2015). Advanced lung cancer inflammation index, a new prognostic score, predicts outcome in patients with small-cell lung cancer. Clin Lung Cancer, 16, 165-71. https://doi.org/10.1016/j.cllc.2015.03.001
  17. Ichinose Y, Yano T, Asoh H, et al (1995). Yokoyama H, Yoshino I, Katsuda Y. Prognostic factors obtained by a pathologic examination in completely resected non-small-cell lung cancer. An analysis in each pathologic stage. J Thorac Cardiovasc Surg, 110, 601-5. https://doi.org/10.1016/S0022-5223(95)70090-0
  18. Jafri SH, Previgliano C, Khandelwal K, Shi R (2015). Cachexia index in advanced non-small-cell lung cancer patients. Clin Med Insights Oncol, 9, 87-93.
  19. Jafri SH, Shi R, Mills G (2013). Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC Cancer, 13, 158-67. https://doi.org/10.1186/1471-2407-13-158
  20. Jing X, Huang C, Zhou H (2015). Association between serum C-reactive protein value and prognosis of patients with non-small cell lung cancer: a meta-analysis. Int J Clin Exp Med, 15, 10633-39.
  21. Kasymjanova G, MacDonald N, Agulnik JS, et al (2010). The predictive value of pre-treatment inflammatory markers in advanced non-small-cell lung cancer. Curr Oncol, 17, 52-8.
  22. Leung EY, Scott HR, McMillan DC (2012). Clinical utility of the pretreatment Glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer. J Thorac Oncol, 7, 655-62. https://doi.org/10.1097/JTO.0b013e318244ffe1
  23. Macchiarini P, Fontanini G, Hardin MJ, et al (1993). Blood vessel invasion by tumor cells predicts recurrence in completely resected T1 N0 M0 non-small-cell lung cancer. J Thorac Cardiovasc Surg, 106, 80-9.
  24. McMillan DC, Watson WS, O'Gorman P, et al (2001). Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. Nutr Cancer, 39, 210-3. https://doi.org/10.1207/S15327914nc392_8
  25. Mo Y, Peng J, Su W, et al (2015). Controversies regarding T status and N status for non-small cell lung cancer. Int J Clin Exp Med, 15, 11675-82.
  26. Moshage HJ, Janssen JA, Franssen JH, Hafkenscheid JC, Yap SH (1987). Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation. J Clin Invest, 79, 1635-41. https://doi.org/10.1172/JCI113000
  27. O'Mahony JB, Palder SB, Wood JJ, et al (1994). Depression of cellular immunity after multiple trauma in the absence of sepsis. J Trauma, 24, 869-75.
  28. Rivas-Fuentes S, Salgado-Aguayo A, Pertuz Belloso S, et al (2015). Role of chemokines in non-small cell lung cancer: angiogenesis and inflammation. J Cancer, 610, 938-52.
  29. Siegel R, Ma J, Zou Z, Jemal A (2014). Cancer statistics. CA Cancer J Clin, 64, 9-29. https://doi.org/10.3322/caac.21208
  30. Sonoda A, Ohnishi S, Nakao S, et al (2015). Factors affecting serum albumin in the perioperative period of colorectal surgery: a retrospective study. BMC Res Notes, 3, 638.
  31. Sun H, Hu P, Shen H, et al (2015). Albumin and neutrophil combined prognostic grade as a new prognostic factor in non-small cell lung cancer: results from a large consecutive cohort. PLoS One, 14, e0144663.
  32. Tomita M, Ayabe T, Chosa E, Nakamura K (2014). Prognostic significance of pre- and postoperative Glasgow prognostic score for patients with non-small cell lung cancer. Anticancer Res, 34, 3137-40.
  33. Trape J, Montesinos J, Catot S, et al (2012). A prognostic score based on clinical factors and biomarkers for advanced non-small cell lung cancer. Int J Biol Markers, 27, 257-62. https://doi.org/10.5301/JBM.2012.9314
  34. Vallieres E, Shepherd FA, Crowley J, et al (2009). The IASLC lung cancer staging project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol, 4, 1049-59. https://doi.org/10.1097/JTO.0b013e3181b27799
  35. Zahorec R (2001). Ratio of neutrophil to lymphocyte counts - Rapid and simple parameter of systemic inflammation and stress in critically ill. Bratisl Lek Listy, 102, 5-14.